Jornay PM

(methylphenidate delayed and extended release capsules) 

 

 

 

 Full Prescribing Information 

 DailyMed Drug Information 

 

 

 

 

 Forms/Strengths 

 

 Capsules: 20 mg, 40 mg, 60 mg, 80 mg, 100 mg 

 

 

 Dosing 

 

 Age: ≥ 6 y/o 

 Onset: delayed until early morning (~10-12 hours after evening dose) 

 Duration: 12-14 hours 

 Considerations: Take in the evening between 6:30-9:30 pm. Capsules can be opened and sprinkled on applesauce. 

 Initial Dose: 20 mg once daily in the evening 

 Titration: 20 mg weekly 

 Max Dose: 60 mg/day 

 

 

 Quick Facts 

 

 Inhibits dopamine/norepinephrine reuptake 

 Enhances focus, attention, and impulse control 

 Extended-release methylphenidate with delayed-release profile designed for bedtime dosing 

 Unique evening dosing provides early morning onset and sustained symptom control throughout the day 

 Common side effects: decreased appetite, insomnia, headache, gastrointestinal discomfort 

 

 

 Indications 

 

   ADHD (ICD-10: F90.0) 

 

 

 Off-Label Uses 

 

   

 

 

 How to Take 

 

 Take once daily in the evening between 6:30 PM and 9:30 PM to allow for morning symptom control. 

 Can be taken with or without food ; high-fat meals may delay absorption. 

 Swallow the capsule whole ; do not crush or chew. 

 If needed, the capsule may be opened and sprinkled on applesauce —consume immediately without chewing. 

 

 

 Side Effects 

 

   

 

 

 Monitoring / Labs 

 

 Cardiovascular : Baseline and routine monitoring of heart rate and blood pressure. 

 Growth in Pediatrics : Regular monitoring of height and weight to detect growth suppression. 

 Psychiatric Symptoms : Observe for mood changes, anxiety, or psychosis. 

 Abuse Potential : Monitor for misuse or diversion. 

 

 

 Education 

 

 

 When to Call the Doctor: 

 

 Severe mood changes, aggression, or suicidal thoughts . 

 Chest pain, rapid heartbeat, shortness of breath ( cardiovascular concerns ). 

 Uncontrolled movements, tics, or worsening anxiety. 

 Numbness, coldness, or color changes in fingers or toes ( circulatory issues ). 

 Unexplained weight loss or delayed growth in pediatric patients . 

 

 

 

 Safety Tips: 

 

 Monitor blood pressure and heart rate , especially in patients with cardiovascular risk. 

 Use caution in patients with anxiety, bipolar disorder, or psychosis , as symptoms may worsen. 

 Avoid caffeine and other stimulants , which may amplify side effects. 

 Ensure adequate hydration and nutrition , as appetite suppression is common. 

 Tapering may be required if discontinuing after long-term use. 

 

 

 

 Parent Tips for Pediatric Patients: 

 

 Encourage a nutrient-dense diet to counteract appetite suppression. 

 Administer exactly as prescribed in the evening for proper morning symptom control. 

 Monitor school performance and behavioral changes . 

 Observe for sleep disturbances ; adjust timing if necessary. 

 Communicate regularly with teachers and caregivers about medication effects. 

 

 

 

 

 

 Additional Information 

 

 

 Contraindications: 

 

 Hypersensitivity to methylphenidate or formulation components. 

 Use within 14 days of MAOI therapy (risk of hypertensive crisis). 

 Symptomatic cardiovascular disease, moderate-to-severe hypertension, hyperthyroidism, glaucoma . 

 History of substance use disorder , unless benefits outweigh risks. 

 

 

 

 Pregnancy: 

 

 Category C ; use only if benefits outweigh risks. 

 May cause neonatal withdrawal symptoms or low birth weight . 

 

 

 

 Lactation: 

 

 Excreted in breast milk ; not recommended due to potential infant exposure. 

 

 

 

 Drug Interactions: 

 

 Serotonergic drugs (e.g., SSRIs, SNRIs, MAOIs) increase serotonin syndrome risk . 

 Acidifying agents (e.g., ascorbic acid) may reduce drug absorption. 

 Alkalinizing agents (e.g., sodium bicarbonate) may increase methylphenidate levels. 

 May potentiate hypertensive effects of certain medications (e.g., decongestants, beta-agonists).